Sorry, you need to enable JavaScript to visit this website.

Multiple Myeloma Resources | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP

Resources to support your practice

Advancing frontline knowledge: KOL expert series on patients with newly diagnosed, transplant-ineligible multiple myeloma

Patient considerations when determining frontline treatment

Dr. Kenneth Shain, Director of the Myeloma Working Group at Moffitt Cancer Center (Tampa, Florida), discusses a typical patient seen in his practice, and how he reviews safety and efficacy data along with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) when choosing a frontline treatment option.

Focus: MM patient

MAIA study on frontline treatment with DARZALEX® + Rd vs Rd alone, including primary results, and post hoc analysis in frail patients

Dr. Ruemu Birhiray, the founder of Indy Hematology Review, explores safety and efficacy data of the MAIA trial, including a post hoc analysis in frail patients.

Focus: frail MM patient

MAIA study of patients on frontline triplet DARZALEX® + Rd vs Rd alone, along with high-risk subgroup analysis

Dr. Kenneth Shain reviews the efficacy and safety of DRd vs Rd from the MAIA trial, including a subgroup analysis in patients with a high-risk cytogenetic profile.

Focus: high-risk MM patient

Rd=lenalidomide (R) + dexamethasone (d).

Dosing and administration guides

Step-by-step instructions on how to administer DARZALEX FASPRO® and DARZALEX®.

Patient identification card

ID card informing healthcare providers about treatment with DARZALEX FASPRO® or DARZALEX®.

Daratumumab and serologic testing brochure

Overview of what to know regarding serological testing interference and daratumumab.

Specialty Distributor list

List of Specialty Distributors and their contact information for ordering DARZALEX FASPRO®.

DARZALEX FASPRO® administration video